Ozempic (semaglutide) and phentermine both get discussed for weight loss, but Ozempic is actually FDA-approved for type 2 diabetes (its weight loss cousin is Wegovy), while phentermine is an older stimulant-based appetite suppressant approved specifically as a short-term weight-loss aid. This guide compares their mechanisms, approved uses, and why they work so differently.
This is general information, not medical advice.
Ozempic vs Phentermine at a glance
| Ozempic (semaglutide) | Phentermine | |
|---|---|---|
| Drug class | GLP-1 receptor agonist | Sympathomimetic amine (stimulant-based appetite suppressant) |
| FDA-approved for | Type 2 diabetes (weight loss is Wegovy’s specific approval) | Short-term (a few weeks) weight loss adjunct |
| Controlled substance | No | Yes, Schedule IV |
| Administration | Once-weekly injection | Daily oral tablet |
| Boxed warning | Thyroid C-cell tumor risk (rodent data) | None |
The most important clarification: Ozempic isn’t FDA-approved for weight loss
Ozempic’s actual FDA approval is for improving blood sugar control in type 2 diabetes, alongside diet and exercise, and (in current labeling) for reducing cardiovascular risk in adults with type 2 diabetes and known heart disease. Semaglutide’s dedicated weight-loss product is Wegovy, approved at a higher maximum dose specifically for chronic weight management. Many people using “Ozempic” as shorthand for semaglutide weight loss are often describing off-label use of the diabetes product, or actually mean Wegovy. This distinction matters for insurance coverage and appropriate use.
How the two work
Semaglutide is a GLP-1 receptor agonist: it mimics a natural gut hormone that stimulates insulin secretion and lowers glucagon secretion, both in a glucose-dependent manner, meaning it works more when blood sugar is high and less when it’s normal. It also slows gastric emptying and affects appetite centers in the brain, which is why it produces weight loss as a side effect (or main effect, in Wegovy’s case) alongside its blood sugar benefits.
Phentermine works through a completely different, older mechanism: it’s a sympathomimetic amine, related structurally to amphetamines, that suppresses appetite primarily through central nervous system stimulation. It doesn’t affect blood sugar regulation directly the way GLP-1 drugs do; its weight-loss effect comes from reduced hunger and increased alertness/energy, a more classically stimulant-driven appetite suppression.
Duration of approved use
Phentermine’s label describes it as indicated for short-term use, specifically “a few weeks,” as an adjunct to diet, exercise, and behavioral modification for patients with a BMI of 30 or higher, or 27 or higher with other risk factors like controlled hypertension, diabetes, or high cholesterol. This short-term framing reflects its original approval era and stimulant properties; long-term phentermine use, while sometimes done in practice, goes beyond its original labeled duration.
Semaglutide products, by contrast, are studied and used for long-term, ongoing treatment; Wegovy’s weight-loss trials ran 68 weeks and longer, and the drugs are generally intended for sustained use rather than a short course.
Side effects and safety considerations
Phentermine, being a stimulant, commonly causes insomnia, increased heart rate and blood pressure, dry mouth, and nervousness, effects tied directly to its sympathomimetic mechanism. As a Schedule IV controlled substance, it also carries some abuse and dependence potential, though considered lower than Schedule II stimulants.
Semaglutide commonly causes gastrointestinal side effects: nausea, vomiting, diarrhea, and constipation, tied to its effect on gastric emptying. It carries a boxed warning regarding thyroid C-cell tumors observed in rodent studies; whether this risk translates to humans hasn’t been determined, but the label specifically flags it and advises caution in patients with a personal or family history of medullary thyroid carcinoma or certain endocrine syndromes.
Who each might suit
Factors that may point toward phentermine:
- A need for a short-term, oral, lower-cost option
- No diabetes diagnosis requiring the additional benefits semaglutide products offer
- No history of cardiovascular issues that would make a stimulant-based appetite suppressant riskier
Factors that may point toward semaglutide (Ozempic if diabetic, or Wegovy specifically for weight loss):
- Type 2 diabetes requiring blood sugar management alongside weight loss
- A need for sustained, long-term weight management rather than a short course
- Willingness to tolerate GI side effects in exchange for generally larger average weight loss seen in semaglutide trials compared with older appetite suppressants
Frequently asked questions
Is Ozempic FDA-approved for weight loss?
No, not directly. Ozempic is approved for type 2 diabetes. Its sister product Wegovy, also semaglutide but at a different maximum dose, is the one specifically approved for chronic weight management.
Is phentermine a stimulant?
Yes, it’s a sympathomimetic amine related structurally to amphetamines, and it’s a Schedule IV controlled substance.
Can phentermine be used long-term?
Its label describes short-term use (a few weeks) as an adjunct to diet and exercise; longer use happens in some clinical practice but goes beyond the original approved duration framing.
Which causes more nausea, semaglutide or phentermine?
Semaglutide’s most common side effects are gastrointestinal (nausea, vomiting, diarrhea), tied to its effect on gastric emptying. Phentermine’s side effects are more stimulant-related (insomnia, increased heart rate) rather than primarily GI.
Does semaglutide carry a cancer warning?
Its label carries a boxed warning about thyroid C-cell tumors seen in rodent studies; human relevance is undetermined, but caution is advised in patients with certain thyroid cancer or endocrine syndrome history.